NovaBridge Biosciences (NASDAQ:NBP) shares are up on Monday following the announcement of positive topline results from the Phase 2a study of VIS-101, a treatment for retinal vascular diseases.
Trial Data
The Phase 2a study results revealed that VIS-101 produced rapid and durable treatment responses with both 3 mg and 6 mg dose cohorts in patients with wet age-related macular degeneration (wet AMD).
Wet AMD affects over 20 million people globally.
VIS-101 demonstrated mean Best Corrected Visual Acuity (BVCA) improvements of >10 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters and median central subfield thickness (CST) reductions of 100-150 mm.
The study enrolled 38 patients in China, demonstrating a favorable safety profile with no dose-limiting toxicity, which positions VIS-101 as a potential best-in-class treatment option.
In addition to the promising efficacy data, the company plans to initiate a dose-determining Phase 2b study in the second half of 2026, followed by a global Phase 3 program in 2027.
In January, NovaBridge Biosciences shared upgrade results from the Phase 1b combination study of givastomig in untreated metastatic gastric cancer patients.
NovaBridge Technical Analysis
Shares of NovaBridge Biosciences have decreased by 23.08% over the past 12 months, indicating a challenging year for the stock.
Currently, the stock is trading 14.2% above its 20-day simple moving average (SMA) and 4.4% above its 50-day SMA, suggesting some short-term strength despite the longer-term downtrend.
The RSI is at 51.92, which is considered neutral territory, indicating that the stock is neither overbought nor oversold. Meanwhile, MACD is at -0.0639, with the signal line at -0.1105, suggesting a bullish signal as the MACD is above the signal line.
The combination of neutral RSI and bullish MACD suggests mixed momentum, indicating that while there is some upward pressure, the stock is not yet in a strong bullish trend.
- Key Resistance: $4.50
- Key Support: $3.50
NBP Price Action: NovaBridge Biosciences shares were up 8.86% at $3.81 at the last check on Monday, according to Benzinga Pro data.
Image via Shutterstock
